ReviewEuropean journal of heart failure2009
Immunological mechanisms of pentoxifylline in chronic heart failure.
Review in European journal of heart failure, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 65 citations in OpenAlex.
- Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy.Muscle & nerve · 2011Trial
- Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis.Journal of veterinary internal medicineTrial
- Premature ovarian insufficiency restoration after chemotherapy: current achievements and future prospects on its treatment or management.Journal of ovarian research · 2025Review
- Cardiogenic Pulmonary Edema in Emergency Medicine.Advances in respiratory medicine · 2023Review
- Modulation of the Acute Inflammatory Response Induced by theAntibiotics (Basel, Switzerland) · 2023Article
- Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy.PLoS neglected tropical diseases · 2023Article
- Modulation of miR-145-5p and miR-146b-5p levels is linked to reduced parasite load in H9C2 Trypanosoma cruzi infected cardiomyoblasts.Scientific reports · 2022Article
- Multi-therapeutic strategy targeting parasite and inflammation-related alterations to improve prognosis of chronic Chagas cardiomyopathy: a hypothesis-based approach.Memorias do Instituto Oswaldo Cruz · 2022Article
- Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy.Frontiers in cellular and infection microbiology · 2021Review
- Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy.Frontiers in cellular and infection microbiology · 2021Article
- Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic.European journal of pharmacology · 2020Review
- Pharmacological management of cardiac cachexia: a review of potential therapy options.Heart failure reviews · 2019Review
- Serum Levels of Inflammatory Cytokines and Expression of BCL2 and BAX mRNA in Peripheral Blood Mononuclear Cells and in Patients with Chronic Heart Failure.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.Clinical reviews in allergy & immunology · 2017Review
- Cardiac Cachexia: Perspectives for Prevention and Treatment.Arquivos brasileiros de cardiologia · 2017Review
- Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease.Antimicrobial agents and chemotherapy · 2016Article
- Therapeutic effects of pentoxifylline on diabetic heart tissue via NOS.Anatolian journal of cardiology · 2016Article
- Pentoxifylline Attenuates Cardiac Remodeling Induced by Tobacco Smoke Exposure.Arquivos brasileiros de cardiologia · 2016Article
- Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.Therapeutics and clinical risk management · 2016Review
- Pentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T-cell response.PLoS neglected tropical diseases · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progressive syndrome of chronic heart failure (CHF) represents a common disease pathway that may be derived from a host of varying insults (including myocardial ischaemia and infarction, hypertension, viral infection, pregnancy, etc). Despite this multifarious aetiology, a common phenomena observed in CHF patients is elevated levels of tumour necrosis factor (TNF)-alpha. This has led to the widespread concept that TNF-alpha is directly involved in the pathophysiology of CHF and as such, attempts have been made to inhibit TNF-alpha production in this cohort. However, to date, there have been no clear beneficial effects from TNF-alpha inhibition and indeed trials of direct anti-TNF therapy have provoked worsening of clinical outcomes. Conversely, a possible exception is pentoxifylline (PTX), a putative TNF-alpha inhibitor with possible (but ill-defined) vasodilatory properties. Several small clinical trials assessing the use of PTX in CHF have suggested beneficial effects on multiple surrogate clinical markers. Interestingly, these trials failed to show a concordant effect on circulating TNF despite the clinical improvement, suggesting other key beneficial properties of this novel agent. This review article provides an insight into the potential beneficial mode of the action of PTX in CHF and calls for more investigation of this interesting agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.